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Beyond the advances made in computer-assisted interventions and robotic systems [1], the 
demand of more efficient and safer therapies remains challenging. Thus, if is it possible today 
to improve the instrument tracking and steering, the target localization, to miniaturize the 
sensors and actuators and to conduct preoperatively planned minimally invasive therapies, we 
still need new resources to achieve permanent destruction of abnormal tissues or suppression 
of pathological processes. Most of the physics-based (or energy-based) therapeutic principles 
at our disposal have been established a long time ago but their actions on basic cellular and 
molecular mechanisms are not yet fully understood. They all have a wide spectrum of clinical 
targets in terms of organs and pathologies, modes of application (external, interstitial, 
intraluminal, etc.) with advantages and side-effect drawbacks, proven indications and 
contraindications. Some of them may still face controversies regarding their outcomes. This 
short paper, mainly focused on tumor destruction, briefly reviews in its first part some of 
these techniques and sketches the next generation under investigation. The formers include 
radiofrequency (RF), high intensity focused ultrasound (HiFU), microwaves and cryotherapy, 
all being temperature-based. Laser-based approaches (e.g. photodynamic therapy at large) are 
also discussed.  Radiotherapy and its variants (hadrontherapy, brachytherapy, Gamma knife 
and Cyberknife) remain of course the reference technique in cancer treatment. The next 
breakthroughs are examined in the second part of the paper. They are based on the close 
association between imaging agents, drugs and some stimulation technique. The on-going 
research efforts in that direction show that, if they are still far from clinical applications, 
strong expectations are made. From the point of view of interventional planning and image 
guidance, all of them share a lot of concerns.  
Improving current therapies 
Hyper- and hypothermia exposures and radiotherapy treatments are aimed at tissue 
destruction. Although complex, the latter has well-established protocols while the former still 
needs guidelines to set the conditions for thermal damage in humans. They have been 
successful for localized tumors through extracorporeal, interstitial or endocavitary uses. 
Imaging guidance is required in order to target the tumor site and to monitor the treatment 
intra-operatively either by independent imaging modalities or by a stand-alone dual-mode 
device integrating imaging and therapeutic capabilities. Imaging objectives and constraints 
depend on multiple factors such as the targeted organs, access paths, and therapeutic process. 
Furthermore, not only energy deposition has to be concentrated on the target while 
minimizing its impact on surrounding tissues and organs as for radiotherapy but it depends on 
multiple parameters to be adjusted and a precise real-time measure of temperature must be 
available.  
Temperature-based therapies 
Radiofrequency ablation (RFA) is based on electric current-mediated heat applied through an 
electrode placed into the target. Resistive heating around the RFA electrode is produced by 
fast ion oscillations at frequency typically ranging over 450-500 kHz [2] [3]. In order to avoid 
different sequential placements into large lesions, multitined electrodes (figure 1) or internal 
electrode cooling is sometimes used. Monopolar and bipolar energy delivery are also 
considered. The surrounding tissue temperature can be directly controlled by sensors located 
in the tips of the electrodes or by measuring the tissue impedance. Atrial fibrillation 
suppression is a major application of this thermoablative technique but applications for 
unresectable cancer increase significantly within the last years. RFA has the advantage of 
small diameter probes but requires 10-25 minutes for treatment. 
Microwave ablation (MWA) is obtained by creating rapid oscillations of water molecules, thus 
causing frictional heating leading to coagulation and necrosis. MWA probes are basically 
coaxial waveguides [4]. Several frequencies, 915 MHz and 2.45 GHz, are authorized and lead 
to treat volumes up to 4-5 cm in diameter. Improvements in antenna design (from triaxial to 
dielectric resonator antenna) have been recently brought with the objective to extend the 
treated area, to better conform the radiation pattern and to reduce the probe size. MWA is 
considered as less affected by the heat sink problem due to the presence of large vessels 
nearby the tumor as compared with RFA and HiFU. Shorter ablation times are achieved but 
minimizing the probe diameter currently reaching a few centimeters remains challenging. 
 
High intensity ultrasound has raised a lot of interest for years [5] and is now widely 
disseminated. Focused transducers, HiFU (High Intensity Focused Ultrasound) and non (or 
weakly) focused transducers, HiCU (High Intensity Contact Ultrasound), operating at a few 
MHz, are marketed (figure 2). They incorporate ultrasound imaging sensors for guidance. The 
energy delivered over a few seconds can induce high temperatures (typically >60°C) and 
generate irreversible tissue necrosis at the target region while not damaging surrounding 
tissues. An active research is conducted in this field and major improvements can be expected 
for a full electronic 3D phased array focusing and miniaturized probes allowing interstitial 
procedures. Today assessed for prostate cancer treatment, they should find a wide spectrum of 
clinical applications. The main technical limitation remains however the time required (e.g. 
few hours) to ablate tumors of large diameters. Another major step is under progress with the 
CMUT (Capacitive Micromachined Ultrasound Transducers) technology [6] which may offer 
better performance in pressure field, bandpass and more flexibility in probe topology design 
than the current piezoelectric technology.  
 
Laser ablation, e.g. laser-induced thermotherapy, is another approach with a large range of 
clinical applications. Light in the near infrared part of the spectrum -- as from a NdYAG laser 
at 1064 nm or a semiconductor diode laser at 805 nm – can be effective up to 10 mm of tissue. 
Beams are transmitted via thin fibers, so that endoscopic procedures can be applied, and 
focused to small spots to destroy tissues. Interstitial laser photocoagulation can be performed 
over a few minutes via fibers through needles at low power (about 3 W, avoiding so tissue 
vaporization, to be compared with the 60-80 W used endoscopically). Low level laser (LLLT) 
[7] is also expected for improving wound healing, repair of soft tissues and relief of pain and 
inflammation. However, like all the physical therapies described here, the key issues rely on a 
precise positioning the fibers in the target area, the control of the extent of laser induced 
necrosis to the tumor volume, therefore, image-guidance is here critical too.  
 
Cryotherapy consists to locally induce very cold temperatures (-75°C) at a catheter tip below  
-75°C which results in irreversible cell destruction within a so-called “ice ball”. The adhesion 
of the tip to the tissue leads to a stable ablation [2] [8]. A recent breakthrough has been made 
by the introduction of argon gas rather than liquid nitrogen. Argon, taking advantage of the 
Joule-Thompson effect, provides a faster cooling of the cryoprobe (figure 3) which 
significantly speeds up the treatment and makes easier the sequential control of freeze-thaw 
cycles (thawing is achieved by helium). Multiple cryoprobes, each with embedded 
thermocouple for temperature monitoring, allow for large tumor ablation as in liver. Although 
this technology evolved significantly the last few years, and can now be performed 
percutaneously with smaller probes facilitating their placement, it is often replaced by RF 
treatment. 
Radiation therapy 
Conventional radiotherapy with photon beams (X-rays) is the main technique and the gold 
standard reference for cancer treatment. Significant steps forward have been made in the 60’s 
and 70’s in medical imaging and the new capabilities offered in 3D visualization of the 
anatomical structures that allowed to better plan and compute radiation dose by taking into 
account the different tissue attenuations. Advances have also been seen with 3D-conformal 
and intensity modulated radiation therapies (IMRT) in order to limit the irradiation of healthy 
tissues, the main concern of all physical therapies as we have seen before. By conforming the 
dose to the target shape, a higher concentration can be achieved while minimizing the impact 
on the selected normal tissues. IMRT makes use of 6-10 beams, coplanar or non-coplanar, 
their intensity being varied across the irradiation field by means of computer controlled 
collimators (“multileaf collimators”). Conformal dose distribution can be improved through 
recent advanced techniques such as Volumetric Modulated Arc Therapy (VMAT) where the 
target is continuously irradiated while the source of the beam is rotated around the patient in 
single or multiple arcs. Sophisticated simulation planning programs (e.g. inverse problem) 
have been or have still to be developed to optimize the dose delivery. External beam therapy 
includes Gamma knife and more recently the fully robotized Cyber knife. Hadrontherapy is a 
new technique, also external, based on non-elementary particles. However, an alternative is 
represented by brachytherapy (also known as curietherapy) where radioactive sources are 
placed inside or near the area to be treated. 
 
Brachytherapy has been considered effective for very different situations (prostate cancer for 
instance). This modality is one of the oldest [9], which may be either temporary or permanent. 
In temporary brachytherapy, the radioactive sources are placed inside or near a tumor for a 
specific amount of time and then withdrawn. Permanent low dose brachytherapy (also called 
“seed” implantation) involves placing radioactive seeds in or near the tumor and leaving them 
until their radioactivity goes to zero (several weeks or months according to the type of used 
radioactive sources). A pre-operative planning, image-based, is required in order to find the 
optimal locations and the amount of time needed to deliver the correct radiation dose. An 
accurate, intra-operative positioning of the sources in patient’s body has to be achieved for a 
successful therapy. The assumption made here is that the radioactive seeds will not shift 
during the overall treatment period. 
 
Gamma Knife can be seen as an advanced step in focused multibeam radiation therapy (for a 
recent review of other radiosurgery systems, X-knife, CyberKnife (figure 4), etc. refer to [10]). 
Originally proposed by the Swedish neurosurgeon Lars Leksell for neurosurgery, Gamma 
Knife is a self-contained unit with 201 Colbat-60 sources mounted in a hemispheric array 
(figure 5) such that gamma ray beams focus to a common point (isocenter). Multiple 
isocenters are used to match the global radiation dose distribution to an irregular tumor 
volume. Its interchangeable collimating helmets allow variation of focusing point size, 
exposing the desired beam diameter such as 4, 8, 14, and 18 mm. An alternative is the 
Rotational Gamma System with 30 Colbat-60 sources arranged in a rotating hemispheric shell 
[11], simulating an infinite number of beams and promoting extremely high target to surface 
dose ratios. Its collimating system is a concentric collimating hemisphere, inside the source 
hemisphere, co-rotating with the sources, to achieve the same desired beam diameters as 
Gamma Knife. Treatment planning (figure 6) is a key subsystem of Gamma Knife, which 
includes the functionality required to import patient images, calculate dose distributions, 
simulate and evaluate treatment plans, verify treatment parameters, and export completed 
plans to the treatment unit. 
 
Hadrontherapy (or charged particle therapy) exploits heavy protons and has the advantage 
over photons or lighter particles to penetrate deeply in the body while transferring almost all 
the energy at the end of their path., the peak dose known as the “Bragg Peak”, allowing thus 
to reduce the dose to the healthy tissues in front [12]. The position of this sharp peak depends 
on the mass and the speed of the particles. Thus, the depth can be controlled by varying the 
beam energy and a homogeneous dose delivered over the whole volume of interest by 
spreading out the Bragg Peak. Heavy ions, such as carbon, have a higher relative biologic 
effectiveness (RBE) than protons and are expected to offer more efficient treatment for deep-
seated tumors. The beam produced by a cyclotron or synchrotron is narrow (4-10 mm 
diameter) and is enlarged by passive scattering or active directional scanning (using magnetic 
fields in such a way that a point-based treatment, intensity modulated, is carried out over the 
target volume). Technically very sound and appealing by its principles, proton therapy has not 
yet demonstrated significant benefits and carbon ion therapy must still be considered as 
experimental. Much more clinical evidence is required according to the high costs involved 
by this technology.  
Multimodal therapy 
As pointed out above, both basic research is required to better understand the physical effects 
of temperature-based therapies on normal and abnormal tissues, and more clinical, multi-
centre and comparative trials are needed. Most of them are today combined with radiotherapy 
techniques leading to the concept of “multimodal therapy”. The motivations can be to make 
use either of their different advantages and effects, or to face a failure of the first applied 
therapy (evidence supports the consideration of cryotherapy and HiFU after external-beam 
radiotherapy, for instance). The multimodal therapy is similar to that known in medical 
imaging for a while. In such case, registration issues, so fundamental in medical robotics, are 
of concern.  As with any other treatment for cancer, appropriate patient selection is critical 
and determines the outcome. 
 
New perspectives for computer-assisted interventions are open when temperature-based 
approaches are applied. Emphasis is put in the literature on the need to design well defined 
planning which is of course of major importance. More critical and challenging in our point of 
view is the adaptive way required to manage the treatment. Ideally, the temperature must be 
not only measured but also controlled in real-time and heat and cooling adjusted accordingly. 
This means to be capable to solve the heat equation for instance (the tissue is heterogeneous 
and vessels play an important role in modifying the boundary conditions) and consequently 
update the treatment plans while the temperature is continuously evolving.  This is a very 
challenging task. The temperature measurement can be available either directly when sensors 
are put on the catheter tip or indirectly through MRI. In the latter case, if additional 
interventional constraints and costs must be taken into account, the high demand in other 
clinical applications for the development of MRI compatible robotic systems should be an 
advantage. High Intensity Ultrasound technique, although still mainly used in a stand-alone 
station, is already concerned. Apart the measure, the benefit is also to access to fully 3D data 
providing reliable and precise positions of the target and the probe.  
Physically-enhanced and image-guided drug therapy 
Beyond the above physical therapies, new approaches are on the way. Drug delivery activated 
by heat, ultrasound or light belongs to these new attempts. Several factors in fact limit the 
molecular target therapies among which the high fluid pressure, the balance to make between 
delivery, determined by perfusion, and accumulation, resulting from permeability. The 
molecular size of the agent has of course also a major role. The first way to improve this 
process consists to modify the drug in order to facilitate the accumulation at the target site. It 
may be performed for instance by adding a carrier vehicle encapsulating the molecule 
(liposomes, nanoparticles or polymers). An alternative is to modify the physiological 
conditions of the tumor in order to decrease its resistance to accumulation and increase the 
perfusion. Dual monitoring low hyperthermia and drug deposit for this purpose is a sound and 
challenging way to do that. If some imaging agent (e.g. probe) is added, tracking the delivery 
becomes effective.  
 
In short, five components represented by a chemotherapeutic drug, a drug delivery vehicle, an 
imaging agent suited for MRI, PET, ultrasound, optical imaging, etc. together with an 
appropriate activation mean, define the next breakthrough to be accomplished. 
Radiofrequency, microwave, ultrasound and light are of interest to boost and control 
intracellular drug delivery. The major impact on cancer treatment that can be expected 
explains the many studies presently conducted on thermosensitive liposomes for example.  
 
Microbubble carriers are a way to deliver drugs and therapeutic genes. Acoustically-driven 
active lipospheres (AALs) are used by Ferrara [13] and when these microbubbles are in place, 
they are fragmented by higher intensity ultrasound, spraying their contents into the target 
tissue. Although focused by now on liposphere delivery to blood vessel walls, this principle 
should have broad applications. The combination of imaging function, release and radiation 
force, with different frequency bands, in a unique transducer could open major clinical 
windows. 
 
Light activated treatment has also a great potential although no applications have not yet fully 
established. This photodynamic therapy (PDT), a cheap therapy, provides treatment with low 
power red light (e.g. laser) after administration of a photosensitizing drug [14]. There is no 
increase in tissue temperature and so collagen and elastin are less affected, preserving 
mechanical properties. Under light illumination at an appropriate wavelength, hydroxy 
radicals or singlet oxygen are produced inducing oxidation and death of tissues. A wide array 
of photosensitizers for PDT exists and is marketed. 
 
 
Conclusion  
 
Many questions remain open in most of the physics-based therapies that we have been shortly 
reviewed. All are based on principles discovered a long time ago and advances are still far 
from being sufficient. Clinical studies do not clarify enough how and when they should be 
used in first intention or sequenced over time. In other words, patients must be cared today 
and not tomorrow. No doubt that they offer many opportunities. New probe and transducer 
design, device miniaturization through MEMS technology will converge with the parallel 
evolution of medical robots, imaging modalities and drug delivery advances. Almost all, if not 
all, physical therapeutic systems described here are basically image-guided and can be merged 
into the medical robot frame. Dual sensing and actuating (or activating) devices are in 
progress, and even if there is a long way from the initial concepts to clinical applications (with 
inherent quality control and traceability), the trend toward more efficient, less invasive care 
will support the efforts made in the field. In parallel, basic research opens new windows. For 
instance, terahertz (THz) imaging (with a frequency range lying between the infrared and 
microwave regions of the spectrum) is just emerging as a biomedical modality. We do not 
know if, in the future, it may not have therapeutic applications [15].  
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Figure 1. Radiofrequency needle electrode. The gauge needle is introduced into the tumor and 
then the retractable tines are deployed. 
 
 
 
  
Figure 2. Computer graphics representation of the HiFU transducer for prostate cancer 
(courtesy EDAP-TMS) 
 
 
 
 
Figure 3. Cryotherapy device. The tip thermocouples offer a temperature feedback that allows 
controlling the flow of refrigerant delivery (Medtronic & CryoCath).  
  
Figure 4. The Cyberknife in the treatment room set-up, based on a Kuka robot (Accuray 
Company).  
 
 
 
Figure 5. Schematic diagram of the Leksell Gamma Knife 4C (Elekta).  
 (a) 
 
 (b) 
 
Figure  6. Illustration of treatment planning and simulation for Rotational Gamma System 
(LIST, Southeast Univ., China). (a) planning for  treatment of a cerebral lesion, (b) simulation 
for treatment of a abdominal lesion. 
 
 
